Abstract
Purpose of review:
Endolymphatic hydrops remains a significant cause of morbidity secondary to vertigo, hearing loss, and tinnitus. The purpose of this report is to summarize the most clinically relevant publications on endolymphatic hydrops over the past 2 years.
Recent findings:
Hydrops has historically been a diagnosis of exclusion, but recent efforts has shown a role for MRI with intratympanic gadolinium. Cochrane reviews of intratympanic dexamethasone and gentamicin found inadequate level 1 evidence to support their use.
Summary:
High-level evidence to guide therapy is lacking. MRI holds potential for definitive diagnosis.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Anti-Bacterial Agents / therapeutic use
-
Contrast Media
-
Endolymphatic Hydrops / complications
-
Endolymphatic Hydrops / diagnosis*
-
Female
-
Follow-Up Studies
-
Hearing Loss, Sensorineural / drug therapy
-
Hearing Loss, Sensorineural / etiology
-
Hearing Loss, Sensorineural / physiopathology*
-
Humans
-
Image Enhancement / methods
-
Magnetic Resonance Imaging / methods
-
Male
-
Meniere Disease / drug therapy
-
Meniere Disease / etiology
-
Meniere Disease / physiopathology*
-
Risk Assessment
-
Tinnitus / drug therapy
-
Tinnitus / etiology
-
Tinnitus / physiopathology*
-
Treatment Outcome
-
Vertigo / drug therapy
-
Vertigo / etiology
-
Vertigo / physiopathology*
Substances
-
Adrenal Cortex Hormones
-
Anti-Bacterial Agents
-
Contrast Media